Musculoskeletal syndromes associated with malignancy (excluding hypertrophic osteoarthropathy)

Current Opinion in Rheumatology

Volumn 20, Issue 1, 2008, Pages 100-105

  Naschitz, Jochanan E ^a   Rosner, Itzhak ^b  

^a BNAI ZION MEDICAL CENTER   (Israel)

^b TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

Author keywords

Cancer; Malignancy; Musculoskeletal disorder; Paraneoplastic syndrome; Rheumatic disorder

Indexed keywords

METHOTREXATE; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

ANKYLOSING SPONDYLITIS; CANCER DIAGNOSIS; CANCER RISK; DERMATOMYOSITIS; DISEASE ASSOCIATION; HUMAN; INCIDENCE; LYMPHOMA; MALIGNANT TRANSFORMATION; MUSCULOSKELETAL DISEASE; NEOPLASM; PARANEOPLASTIC SYNDROME; POLYMYOSITIS; PRIORITY JOURNAL; REVIEW; RHEUMATIC DISEASE; RHEUMATOID ARTHRITIS; SJOEGREN SYNDROME; SYSTEMIC LUPUS ERYTHEMATOSUS; SYSTEMIC SCLEROSIS;

HUMANS; MUSCULOSKELETAL DISEASES; NEOPLASMS; PARANEOPLASTIC SYNDROMES; RHEUMATIC DISEASES;

EID: 40349091237     PISSN: 10408711     EISSN: None     Source Type: Journal    
DOI: 10.1097/BOR.0b013e3282f1ecd4     Document Type: Review

References (48)

1. Naschitz JE. Rheumatic syndromes: clues to occult neoplasia. Curr Opin Rheumatol 2001; 13:62-66.
2. Andras C, Csiki Z, Ponyi A, et al. Paraneoplastic rheumatic syndromes. Rheumatol Int 2006; 26:376-382. Systematic review and vast personal experience of the authors.
3. Hill AB. The environment and disease: association or causation? Proc R Soc Med 1965; 58:293-300.
4. Villa AR, Kraus A, Alarcon-Segovia D. Autoimmune rheumatic diseases and cancer: evidence of causality? In: Shoenfeld Y, Gershwin ME, editors. Cancer and autoimmunity. Amsterdam: Elsevier; 2000. pp. 111-117.
5. Van Reekum R, Streiner DL, Conn DK. Applying Bradford Hill's Criteria for Causation to Neuropsychiatry. Challenges and Opportunities. Neuropsychiatry Clin Neurosci 2001; 13:318-325.
6. Hill CL, Zhang Y, Sigurgeirsson B, et al. Frequency of specific cancer types in dermatomyositis and polymyositis: a population-based study. Lancet 2001; 357:96-100.
7. Buchbinder R, Forbes A, Hall S, et al. Incidence of malignant disease in biopsy-proven inflammatory myopathy. A population-based cohort study. Ann Intern Med 2001; 134:1087-1095.
8. Fiorentino D, Callen J. Dermatomyositis. In: Williams H, Bigby M, Diepgen T, et al., editors. Evidence-based Dermatology. 2nd ed. Blackwell; 2003.
9. Ponyi A, Constantin T, Garami M, et al. Cancer-associated myositis: clinical features and prognostic signs. Ann N Y Acad Sci 2005; 1051:64-71.
10. Chen YJ, Wu CY, Shen JL. Predicting factors of malignancy in dermatomyositis and polymyositis: a case-control study. Br J Dermatol 2001; 144:825-831.
11. Levine SM. Cancer and myositis: new insights into an old association. Curr Opin Rheumatol 2006; 18:620-624. Remarkable and enlightening.
12. Casciola-Rosen L, Nagaraju K, Plotz P, et al. Enhanced autoantigen expression in regenerating muscle cells in idiopathic inflammatory myopathy. J Exp Med 2005; 201:591-601.
13. Okada T, Noji S, Goto Y, et al. Immune responses to DNA mismatch repair enzymes hMSH2 and hPMS1 in patients with pancreatic cancer, dermatomyositis and polymyositis. Int J Cancer 2005; 116:925-933.
14. Tallai B, Flasko T, Gyorgy T, et al. Prostate cancer underlying acute, definitive dermatomyositis: successful treatment with radical perineal prostatectomy. Clin Rheumatol 2006; 25:119-120.
15. Yoshinaga A, Hayashi T, Ishii N, et al. Successful cure of dermatomyositis after treatment of nonseminomatous testicular cancer. Int J Urol 2005; 12:593-595.
16. Darnell RB, DeAngelis LM. Regression of small-cell lung carcinoma in patients with paraneoplastic neuronal antibodies. Lancet 1993; 341:21-22.
17. Guegan S, Poszepczynska-Guigne E, Wechsler J, et al. Severe necrotic and haemorrhagic edema of the upper limbs revealing remitting seronegative symmetrical synovitis with pitting edema. Ann Dermatol Venereol 2006; 133:795-798.
18. Liozon E, Loustaud V, Fauchais AL, et al. Concurrent temporal (giant cell) arteritis and malignancy: report of 20 patients with review of the literature. J Rheumatol 2006; 33:1606-1614. Patients with and without malignancy seem almost indistinguishable regarding features and outcome of TA.
19. Yanagi T, Matsumura T, Kamekura R, et al. Relapsing polychondritis and malignant lymphoma: is polychondritis paraneoplastic? Arch Dermatol 2007; 143:89-90. An update.
20. Ekstrom K, Hjalgrim H, Brandt L, et al. Risk of malignant lymphomas in patients with rheumatoid arthritis and in their first-degree relatives. Arthritis Rheum 2003; 48:963-970.
21. Bernatsky S, Ramsey-Goldman R, Clarke A. Malignancy and autoimmunity. Curr Opin Rheumatol 2006; 18:129-134. A remarkable review of present knowledge.
22. Mellemkjaer L, Linet MS, Gridley G, et al. Rheumatoid arthritis and cancer risk. Eur J Cancer 1996; 32A:1753-1757.
23. Gridley G, McLaughlin JK, Ekbom A, et al. Incidence of cancer among patients with rheumatoid arthritis. J Natl Cancer Inst 1993; 85:307-311.
24. Baron JA. Epidemiology of nonsteroidal anti-inflammatory drugs and cancer. Prog Exp Tumor Res 2003; 37:1-24.
25. Askling J, Fored CM, Baecklund E, et al. Haematopoietic malignancies in rheumatoid arthritis: lymphoma risk and characteristics after exposure to tumour necrosis factor antagonists. Ann Rheum Dis 2005; 64:1414-1420.
26. Wolfe F, Michaud K. Lymphoma in rheumatoid arthritis: the effect of methotrexate and antitumor necrosis factor therapy in 18,572 patients. Arthritis Rheum 2004; 50:1740-1751.
27. Landgren O, Engels EA, Pfeiffer RM, et al. Autoimmunity and susceptibility to Hodgkin lymphoma: a population-based case-control study in Scandinavia. J Natl Cancer Inst 2006; 98:1321-1330. An excellent population-based study.
28. Martin T, Weber JC, Levallois H, et al. Salivary gland lymphomas in patients with Sjögren's syndrome may frequently develop from rheumatoid factor B cells. Arthritis Rheum 2000; 43:908-916.
29. Starkebaum G, Sasso EH. Hepatitis C and B cells: induction of autoimmunity and lymphoproliferation may reflect chronic stimulation through cell-surface receptors. J Rheumatol 2004; 31:416-418.
30. Lenze D, Berg E, Volkmer-Engert R, et al. Influence of antigen on the development of MALT lymphoma. Blood 2006; 107:1141-1148.
31. Mariette X, Cazals-Hatem D, Warszawki J, et al. Lymphomas in rheumatoid arthritis patients treated with methotrexate: a 3-year prospective study in France. Blood 2002; 99:3909-3915.
32. Baecklund E, Iliadou A, Askling J, et al. Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis. Arthritis Rheum 2006; 54:692-701. Remarkable study showing that high inflammatory activity, rather than its treatment, is a major risk determinant of lymphoma.
33. Nadkarni S, Mauri C, Ehrenstein MR. Anti-TNF-{alpha} therapy induces a distinct regulatory T cell population in patients with rheumatoid arthritis via TGF-{beta}. J Exp Med 2007; 204:33-39. How long is the distance from the bench to bedside?
34. Saleem B, Nizam S, Emery P. Can remission be maintained with or without further drug therapy in rheumatoid arthritis? Clin Exp Rheumatol 2006; 24:S033-S036. Conclusions of this study are challenging and fervent discussions.
35. Van Der Kooij SM, van der Bijl AE, Allaart CF, et al. Remission induction in early rheumatoid arthritis with initial infliximab and methotrexate therapy: The Disease Course After IFX Discontinuation in The BeSt Trial [abstract]. Arthritis Rheum 2006; 54 (Suppl):S302.
36. Bongartz T, Sutton AJ, Sweeting MJ, et al. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 2006; 295:2275-2285. Conclusions of this paper were challenged by later publications.
37. Breedveld FC, Weisman MH, Kavanaugh AF, et al. The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum 2006; 54:26-37. An important study.
38. Bernatsky S, Boivin J-F, Joseph L, et al. An international cohort study of cancer in SLE. Arthritis Rheum 2005; 52:1481-1490.
39. Chatterjee S, Dombi GW, Severson RK, et al. Risk of malignancy in scleroderma: a population-based cohort study. Arthritis Rheum 2005; 52:2415-2424.
40. Derk CT, Rasheed M, Spiegel JR, et al. Increased incidence of carcinoma of the tongue in patients with systemic sclerosis. J Rheumatol 2005; 32:637-641.
41. Smedby KE, Hjalgrim H, Askling J, et al. Autoimmune and chronic inflammatory disorders and risk of non-Hodgkin lymphoma by subtype. J Natl Cancer Inst 2006; 98:51-60. The evidence is in agreement with previous observations.
42. Soderberg KC, Jonsson F, Winqvist O, et al. Autoimmune diseases, asthma and risk of haematological malignancies: a nationwide case-control study in Sweden. Eur J Cancer 2006; 42:3028-3033. A nationwide case-control study.
43. Saito M, Fukuda T, Shiohara T, et al. Angioimmunoblastic T-cell lymphoma: a relatively common type of T-cell lymphoma in Sjogren's syndrome. Clin Exp Rheumatol 2005; 23:888-890.
44. Askling J, Klareskog L, Blomqvist P, et al. Risk for malignant lymphoma in ankylosing spondylitis: a nationwide Swedish case-control study. Ann Rheum Dis 2006; 65:1184-1187. A nationwide case-control study.
45. Waldman SA, Terzic A. Translating MicroRNA Discovery Into Clinical Biomarkers in Cancer. JAMA 2007; 297:1923-1925.
46. Solans-Laque R, Perez-Bocanegra C, Salud-Salvia A, et al. Clinical significance of antinuclear antibodies in malignant diseases: association with rheumatic and connective tissue paraneoplastic syndromes. Lupus 2004; 13:159-164.
47. Ramos-Casals M. Hypocomplementemia in systemic lupus erythematosus and primary antiphospholipid syndrome: prevalence and clinical significance in 667 patients. Lupus 2004; 13:777-783.
48. Brito-Zeron P, Ramos-Casals M, Nardi N, et al. Circulating monoclonal immunoglobulins in Sjögren syndrome: prevalence and clinical significance in 237 patients. Medicine 2005; 84:90-97.